Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Amneal Pharmaceuticals, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-89.1% vs price
Base Case (Median)
-47.3% vs price
Bull Case (75th pct.)
-44.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $21.78 | 6.6% | High (40%) |
| PE Comparable | $10.78 | -47.3% | Medium (25%) |
| EV/EBITDA | $11.38 | -44.3% | Medium (20%) |
| EV/FCF | $0.47 | -97.7% | Medium (20%) |
| Earnings Power Value | $2.22 | -89.1% | Medium (50%) |
Based on 5 out of 7 methods, AMRX appears overvalued at the current price of $20.44. The base case fair value of $10.78 implies 47.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.